# US 2012/0251520 A1 · Ace2 activation for treatment of heart, lung and kidney disease and hypertension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251520 A1
- Document ID: US20120251520A1
- Status: Published application
- Kind: A1
- Application number: 13/484,585
- Filed: 2012-05-31
- Published: 2012-10-04
- Earliest claimed: 2002-06-19
- Assignees: Apeiron Biologics AG
- Inventors: Joseph Penninger; Michael A. Crackower
- Web page: https://patentgrep.com/patent/US20120251520A1

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/0276: Knock-out vertebrates
- A61K 38/4813: {Exopeptidases (3.4.11. to 3.4.19)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/48: acting on peptide bonds (3.4)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q 2600/172: Haplotypes
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

ACE2 activating compounds for prevention and treatment of cardiovascular disease, kidney disease, lung disease and hypertension are disclosed. Also disclosed are methods of diagnosing cardiovascular disease, kidney disease, lung disease and hypertension by measuring ACE2 expression or nucleotide polymorphism analysis.

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

A method of treating acute lung injury in a human patient comprising administering an effective amount of an active human ACE2 polypeptide to a human patient.

### Claim 33 (depends on 32)

The method according to claim 32, where in the ACE2 polypeptide comprises an active fragment of SEQ ID NO: 2.

### Claim 34

A method of treating acute lung injury in a human patient comprising administering an effective amount of an active human soluble ACE2 polypeptide to a human patient.

### Claim 35 (depends on 34)

The method according to claim 34, where in the ACE2 polypeptide comprises an active fragment of SEQ ID NO. 2.
